Drugs / Poseltinib
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03099148 | Apr → May 2017 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03083561 | Mar → May 2017 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02914379 | Sep → Nov 2016 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01765478 | Jan 2013 → Nov 2014 | rheumatoid arthritis | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07269639 | Jan 2026 → Dec 2027 expected | large B-cell lymphoma | Seoul National University Hospital | Not yet recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06737250 | Nov 2024 → Jun 2026 overdue | primary central nervous system lymphoma | NOBO Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT05335018 | May 2022 → Nov 2025 overdue | diffuse large B-cell lymphoma | Seoul National University Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02628028 | Aug 2016 → Apr 2018 | rheumatoid arthritis | Eli Lilly and Company | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Poseltinib | “OBJECTIVE: To evaluate the efficacy and safety of poseltinib (formerly LY3337641/HM71224), an irreversible covalent inhibitor of Bruton's tyrosine kinase in a 2-part, phase II...” PMID 33323529 ↗ Dec 20203“NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL” NCT06737250 ↗ |
| Known as | HM71224 | “OBJECTIVE: To evaluate the efficacy and safety of poseltinib (formerly LY3337641/HM71224), an irreversible covalent inhibitor of Bruton's tyrosine kinase in a 2-part, phase II...” PMID 33323529 ↗ Dec 2020 |
| Known as | LY3337641 | “OBJECTIVE: To evaluate the efficacy and safety of poseltinib (formerly LY3337641/HM71224), an irreversible covalent inhibitor of Bruton's tyrosine kinase in a 2-part, phase II...” PMID 33323529 ↗ Dec 2020 |
| Known as | NB02 | “NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL” NCT06737250 ↗ |
| Action | Inhibit | “HM71224 is a potent small molecule inhibitor of Bruton's tyrosine kinase (BTK).” NCT01765478 ↗ |
| Modality | Small molecule | “HM71224 is a potent small molecule inhibitor of Bruton's tyrosine kinase (BTK).” NCT01765478 ↗ |
| Route | Oral | “single and multiple oral dose administration of HM71224” NCT01765478 ↗ |
| Target | BTK | “HM71224 is a potent small molecule inhibitor of Bruton's tyrosine kinase (BTK).” NCT01765478 ↗ |